Incomplete chimerism in erythroid, myeloid and B lymphocyte lineage after T cell-depleted allogeneic bone marrow transplantation.
In 22 transplant patients who received T cell-depleted allogeneic bone marrow (alloBMT) we investigated the chimeric state using a mixed agglutination technique and isoenzyme determinations for the red cell lineage, an isoenzyme assay for the myeloid cells, immunoglobulin allotyping for B lymphocytes and cytogenetics for karyotyping. The median duration of follow-up for these patients was 25 months after BMT. Chimerism was evaluated after 6 months. In 14 (64%) of the 22 patients incomplete chimerism was found when the results of the different techniques were combined. Recipient type cells were detected in the red cell lineage in 36% of cases, recipient type myeloid cells in 7% of cases and recipient type mitotic cells in 25% of cases where the marker could provide discrimination. In 100% of the evaluable patients recipient type immunoglobulins persisted after BMT. The data indicate a high frequency of incomplete chimerism following T cell-depleted BMT which involved the broad series of hematological lineages. This frequency appears higher than that following non-T cell-depleted BMT.
Schouten
H C
HC
Department of Hematology, Dr Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
Sizoo
W
W
van 't Veer
M B
MB
Hagenbeek
A
A
Löwenberg
B
B
D000741:Anemia, Aplastic / Q000276:immunology / Q000628:therapy; D001402:B-Lymphocytes / Q000276:immunology; D016026:Bone Marrow Transplantation; D002678:Chimera; D004912:Erythrocytes / Q000276:immunology; D006086:Graft vs Host Disease / Q000276:immunology; D006412:Hematopoietic Stem Cells / Q000276:immunology; D006801:Humans; D007136:Immunoglobulins / Q000378:metabolism; D007938:Leukemia / Q000276:immunology / Q000628:therapy; D008212:Lymphocyte Depletion; D013601:T-Lymphocytes / Q000276:immunology
D007136:Immunoglobulins